Telaprevir

被引：43

作者：

Revill, P. ^{[1
]}

Serradell, N. ^{[1
]}

Bolos, J. ^{[1
]}

Rosa, E. ^{[1
]}

机构：

[1] Prous Sci, Barcelona 08080, Spain

来源：

DRUGS OF THE FUTURE | 2007年 / 32卷 / 09期

关键词：

D O I：

10.1358/dof.2007.032.09.1138229

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Telaprevir is an investigational oral hepatitis C virus (HCV) protease inhibitor in phase 11 evaluation in combination with pegylated interferon and ribavirin for the treatment of chronically infected patients wit genotype 1 hepatitis C. Interim results from a phase 11 trial indicated that this drug has the potential to shorten the duration of treatment for some patients with genotype 1 HCV. Additional phase 11 trials involve the treatment of patients who have failed previous interferon-based treatment, as well as treatment in the absence of ribavirin.

引用

页码：788 / 798

页数：11

共 66 条

[1] Epidemiology of hepatitis C virus infection [J].